🔗 Permalink

Inventor profile of:

THOMAS SCIASCIA

City:

BELMONT, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2026-01-22

Top Assignees for applications by THOMAS SCIASCIA

The entities that hold a legal rights for patent applications filed by inventor SCIASCIA THOMAS:

TREVI THERAPEUTICS, INC. 7 NEW HAVEN, CT United States
Endo Pharmaceuticals Inc. 6 Malvern, PA United States
PENWEST PHARMACEUTICALS CO. 3 CHADDS FORD, PA United States
Penwest Pharmaceuticals Co. 2 Patterson, NY United States
Penwest Pharmaceuticals Co. 1 Wappingers, NY United States
Endo Pharmaceuticals Inc 1 Chadds Ford, PA United States

Recent patent applications by SCIASCIA THOMAS

THOMAS SCIASCIA from BELMONT, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-01-22

US20260021090A1

Human necessities

METHODS OF ADMINISTERING NALBUPHINE

#2 | 2025-11-06

US20250339424A1

Human necessities

TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA

#3 | 2025-07-03

US20250213552A1

Human necessities

METHODS OF ADMINISTERING NALBUPHINE

#4 | 2025-01-30

US20250032480A1

Human necessities

METHODS FOR TREATING PRURITUS

#5 | 2024-12-26

US20240423975A1

Human necessities

TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA

#6 | 2023-10-26

US20230338367A1

Human necessities

TREATMENT OF PRURIGO NODULARIS

#7 | 2022-12-29

US20220409613A1

Human necessities

TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA

#8 | 2022-11-03

US20220347171A1

Human necessities

TREATMENT OF PRURIGO NODULARIS

#9 | 2022-08-25

US20220265640A1

Human necessities

Methods of administering nalbuphine

#10 | 2022-07-14

US20220218697A1

Human necessities

Treatment of chronic cough, breathlessness and dyspnea

#11 | 2020-01-23

US20200022974A1

Human necessities

TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA

#12 | 2020-01-16

US20200016150A1

Human necessities

TREATMENT OF THE PRURITIC SYMPTOMS OF LIVER DISEASE

#13 | 2019-04-25

US20190117576A1

Human necessities

Sustained release formulations of nalbuphine

#14 | 2019-04-04

US20190099416A1

Human necessities

METHODS FOR TREATING PRURITUS

#15 | 2018-05-10

US20180125840A1

Human necessities

TREATMENT OF PRURIGO NODULARIS

#16 | 2018-02-15

US20180042852A1

Human necessities

Sustained release formulation of nalbuphine

#17 | 2018-01-11

US20180008592A1

Human necessities

TREATMENT OF UREMIC PRURITUS

#18 | 2017-08-03

US20170216277A1

Human necessities

THERAPEUTIC USE OF NALBUPHINE WITHOUT AQUARETIC EFFECTS

#19 | 2017-01-05

US20170000782A1

Human necessities

METHODS FOR TREATING PRURITUS

#20 | 2016-12-01

US20160346273A1

Human necessities

Methods for treating pruritus

#21 | 2016-09-15

US20160263035A1

Human necessities

SUSTAINED RELEASE FORMULATION OF NALBUPHINE

#22 | 2015-12-17

US20150359789A1

Human necessities

METHODS FOR TREATING PRURITUS

#23 | 2015-01-27

US14450131

Methods for treating pruritis

#24 | 2014-11-27

US20140350042A1

Human necessities

METHODS FOR TREATING PRURITUS

#25 | 2014-10-23

US20140315937A1

Human necessities

Sustained release formulation of nalbuphine

#26 | 2014-09-18

US20140271852A1

Human necessities

Sustained release formulation of nalbuphine

#27 | 2014-06-26

US20140179727A1

Human necessities

METHODS FOR TREATING PRURITUS

#28 | 2014-06-19

US20140171459A1

Human necessities

Methods for treating pruritus

#29 | 2013-06-27

US20130164350A1

Human necessities

Sustained release formulation of nalbuphine

#30 | 2009-01-29

US20090030026A1

Human necessities

Sustained release formulations of nalbuphine

#31 | 2007-08-23

US20070196482A1

Human necessities

Sustained release torsemide dosage forms

#32 | 2007-03-01

US20070048376A1

Human necessities

Sustained release formulations of nalbuphine

#33 | 2005-08-04

US20050169991A1

Human necessities

Sustained release torsemide dosage forms

InventorID:

311608 ⎘